{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T21:22:22Z","timestamp":1772227342818,"version":"3.50.1"},"reference-count":83,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.mehy.2011.11.008","type":"journal-article","created":{"date-parts":[[2011,12,11]],"date-time":"2011-12-11T01:50:03Z","timestamp":1323568203000},"page":"305-311","source":"Crossref","is-referenced-by-count":8,"title":["Drugs of the future for Peyronie\u2019s disease"],"prefix":"10.1016","volume":"78","author":[{"given":"Serap","family":"Gur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip J.","family":"Kadowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wayne J.G.","family":"Hellstrom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2011.11.008_b0005","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1743-6109.2008.01081.x","article-title":"Peyronie\u2019s disease intervention trials: methodological challenges and issues","volume":"6","author":"Muller","year":"2009","journal-title":"J Sex Med"},{"key":"10.1016\/j.mehy.2011.11.008_b0010","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrurol.2010.24","article-title":"Treatment of Peyronie\u2019s disease with PDE5 inhibitors: an antifibrotic strategy","volume":"7","author":"Gonzalez-Cadavid","year":"2010","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.mehy.2011.11.008_b0015","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0022-5347(01)65368-0","article-title":"Scar contracture: cellular and connective tissue aspects in Peyronie\u2019s disease","volume":"157","author":"Ehrlich","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.mehy.2011.11.008_b0020","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0022-5347(05)64578-8","article-title":"A retrospective review of 307 men with Peyronie\u2019s disease","volume":"168","author":"Kadioglu","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.mehy.2011.11.008_b0025","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ucl.2007.08.017","article-title":"Peyronie\u2019s disease","volume":"34","author":"Taylor","year":"2007","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.mehy.2011.11.008_b0030","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0022-5347(01)65361-8","article-title":"Proposal: trauma as the cause of the Peyronie\u2019s lesion","volume":"157","author":"Devine","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.mehy.2011.11.008_b0035","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1046\/j.1464-410X.1997.26511.x","article-title":"Structural alterations in the tunica albuginea of the penis: impact of Peyronie\u2019s disease, ageing and impotence","volume":"79","author":"Akkus","year":"1997","journal-title":"Br J Urol"},{"key":"10.1016\/j.mehy.2011.11.008_b0040","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0022-5347(01)65367-9","article-title":"Fibrin deposition in Peyronie\u2019s disease plaque","volume":"157","author":"Somers","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.mehy.2011.11.008_b0045","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.urology.2005.01.010","article-title":"Peyronie\u2019s disease associated with increase in plasminogen activator inhibitor in fibrotic plaque","volume":"65","author":"Davila","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.mehy.2011.11.008_b0050","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S1089-8603(02)00124-6","article-title":"Effect of nitric oxide on the differentiation of fibroblasts into myofibroblasts in the Peyronie\u2019s fibrotic plaque and in its rat model","volume":"7","author":"Vernet","year":"2002","journal-title":"Nitric Oxide"},{"issue":"Suppl 5","key":"10.1016\/j.mehy.2011.11.008_b0055","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1038\/sj.ijir.3901082","article-title":"Expanding the paradigm for plaque development in Peyronie\u2019s disease","volume":"15","author":"Mulhall","year":"2003","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.mehy.2011.11.008_b0060","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1161\/CIRCRESAHA.110.217737","article-title":"Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation","volume":"106","author":"Leask","year":"2010","journal-title":"Circ Res"},{"key":"10.1016\/j.mehy.2011.11.008_b0065","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S0022-5347(17)53917-8","article-title":"Cell culture of Peyronie\u2019s disease plaque and normal penile tissue","volume":"127","author":"Somers","year":"1982","journal-title":"J Urol"},{"key":"10.1016\/j.mehy.2011.11.008_b0070","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/sj.ijir.3900874","article-title":"Peyronie\u2019s disease cell culture models: phenotypic, genotypic and functional analyses","volume":"14","author":"Mulhall","year":"2002","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.mehy.2011.11.008_b0075","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/j.1743-6109.2008.00847.x","article-title":"Profibrotic role of myostatin in Peyronie\u2019s disease","volume":"5","author":"Cantini","year":"2008","journal-title":"J Sex Med"},{"key":"10.1016\/j.mehy.2011.11.008_b0080","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1146\/annurev.biochem.67.1.753","article-title":"TGF-beta signal transduction","volume":"67","author":"Massague","year":"1998","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.mehy.2011.11.008_b0085","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1096\/fj.03-1273rev","article-title":"TGF-beta signaling and the fibrotic response","volume":"18","author":"Leask","year":"2004","journal-title":"FASEB J"},{"key":"10.1016\/j.mehy.2011.11.008_b0090","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.cellsig.2008.01.006","article-title":"Targeting the TGFbeta, endothelin-1 and CCN2 axis to combat fibrosis in scleroderma","volume":"20","author":"Leask","year":"2008","journal-title":"Cell Signal"},{"key":"10.1016\/j.mehy.2011.11.008_b0095","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1111\/j.1743-6109.2010.01753.x","article-title":"Transforming growth factor (TGF)-beta type I receptor kinase (ALK5) inhibitor alleviates profibrotic TGF-beta1 responses in fibroblasts derived from Peyronie\u2019s plaque","volume":"7","author":"Piao","year":"2010","journal-title":"J Sex Med"},{"key":"10.1016\/j.mehy.2011.11.008_b0100","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1016\/j.juro.2009.01.097","article-title":"Losartan preserves erectile function after bilateral cavernous nerve injury via antifibrotic mechanisms in male rats","volume":"181","author":"Canguven","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.mehy.2011.11.008_b0105","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/j.1743-6109.2006.00235.x","article-title":"Differences between Candesartan and hydralazine in the protection of penile structures in spontaneously hypertensive rats","volume":"3","author":"Mazza","year":"2006","journal-title":"J Sex Med"},{"key":"10.1016\/j.mehy.2011.11.008_b0110","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/sj.bjp.0707269","article-title":"Different profiles of Ca2+ responses to endothelin-1 and PDGF in liver myofibroblasts during the process of cell differentiation","volume":"151","author":"Kojima","year":"2007","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.mehy.2011.11.008_b0115","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1002\/art.23134","article-title":"Endothelin is a downstream mediator of profibrotic responses to transforming growth factor beta in human lung fibroblasts","volume":"56","author":"Shi-wen","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.mehy.2011.11.008_b0120","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/07853890410018925","article-title":"Role of endothelin in fibrosis and anti-fibrotic potential of bosentan","volume":"37","author":"Clozel","year":"2005","journal-title":"Ann Med"},{"key":"10.1016\/j.mehy.2011.11.008_b0125","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.cardiores.2007.02.008","article-title":"TGF-beta signaling in vascular fibrosis","volume":"74","author":"Ruiz-Ortega","year":"2007","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.mehy.2011.11.008_b0130","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.cytogfr.2008.01.002","article-title":"Regulation and function of connective tissue growth factor\/CCN2 in tissue repair, scarring and fibrosis","volume":"19","author":"Shi-Wen","year":"2008","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.mehy.2011.11.008_b0135","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1177\/039156031007700303","article-title":"Safety and tolerability of local treatment with Iloprost in patients with Peyronie\u2019s disease. A phase 1 pilot study and proposal of a new symptom questionnaire","volume":"77","author":"Pavone","year":"2010","journal-title":"Urologia"},{"key":"10.1016\/j.mehy.2011.11.008_b0140","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/S0006-291X(02)00765-9","article-title":"Upregulation of monocyte chemoattractant protein 1 and effects of transforming growth factor-beta 1 in Peyronie\u2019s disease","volume":"295","author":"Lin","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.mehy.2011.11.008_b0145","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1152\/physrev.1999.79.4.1283","article-title":"Mechanism of action and in vivo role of platelet-derived growth factor","volume":"79","author":"Heldin","year":"1999","journal-title":"Physiol Rev"},{"key":"10.1016\/j.mehy.2011.11.008_b0150","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1182\/blood-2004-04-1485","article-title":"PDGF-D induces macrophage recruitment, increased interstitial pressure, and blood vessel maturation during angiogenesis","volume":"104","author":"Uutela","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.mehy.2011.11.008_b0155","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.cytogfr.2004.03.006","article-title":"Regulation of PDGF and its receptors in fibrotic diseases","volume":"15","author":"Bonner","year":"2004","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.mehy.2011.11.008_b0160","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1161\/ATVBAHA.108.178558","article-title":"PDGF-A, -C, and -D but not PDGF-B increase TGF-beta1 and chronic rejection in rat cardiac allografts","volume":"29","author":"Tuuminen","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.mehy.2011.11.008_b0165","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.2353\/ajpath.2006.060196","article-title":"Platelet-derived growth factor-beta receptor activation is essential for fibroblast and pericyte recruitment during cutaneous wound healing","volume":"169","author":"Rajkumar","year":"2006","journal-title":"Am J Pathol"},{"key":"10.1016\/j.mehy.2011.11.008_b0170","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1096\/fj.07-105627","article-title":"Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis","volume":"22","author":"Akhmetshina","year":"2008","journal-title":"FASEB J"},{"key":"10.1016\/j.mehy.2011.11.008_b0175","first-page":"332","article-title":"Intedanib, a triple kinase inhibitor of VEGFR, FGFR and PDGFR for the treatment of cancer and idiopathic pulmonary fibrosis","volume":"13","author":"Antoniu","year":"2010","journal-title":"IDrugs"},{"key":"10.1016\/j.mehy.2011.11.008_b0180","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1517\/14656566.2010.496453","article-title":"Sorafenib: a clinical and pharmacologic review","volume":"11","author":"Iyer","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.mehy.2011.11.008_b0185","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1358\/dnp.2006.19.2.977444","article-title":"Inhibition of ALK5 as a new approach to treat liver fibrotic diseases","volume":"19","author":"de Gouville","year":"2006","journal-title":"Drug News Perspect"},{"key":"10.1016\/j.mehy.2011.11.008_b0190","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/j.1743-6109.2009.01216.x","article-title":"IN-1130, a novel transforming growth factor-beta type I receptor kinase (activin receptor-like kinase 5) inhibitor, promotes regression of fibrotic plaque and corrects penile curvature in a rat model of Peyronie\u2019s disease","volume":"6","author":"Ryu","year":"2009","journal-title":"J Sex Med"},{"key":"10.1016\/j.mehy.2011.11.008_b0195","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1210\/en.2004-0209","article-title":"Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo","volume":"145","author":"Samuel","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.mehy.2011.11.008_b0200","doi-asserted-by":"crossref","first-page":"10681","DOI":"10.1016\/S0021-9258(18)87000-4","article-title":"Relaxin modulates synthesis and secretion of procollagenase and collagen by human dermal fibroblasts","volume":"265","author":"Unemori","year":"1990","journal-title":"J Biol Chem"},{"key":"10.1016\/j.mehy.2011.11.008_b0205","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1523-1755.2005.00384.x","article-title":"The antifibrotic effects of relaxin in human renal fibroblasts are mediated in part by inhibition of the Smad2 pathway","volume":"68","author":"Heeg","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.mehy.2011.11.008_b0210","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1096\/fj.08-120857","article-title":"Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2","volume":"23","author":"Mookerjee","year":"2009","journal-title":"FASEB J"},{"key":"10.1016\/j.mehy.2011.11.008_b0215","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2165\/00003495-200666080-00002","article-title":"Chronic graft-versus-host disease: pathogenesis and clinical management","volume":"66","author":"Perez-Simon","year":"2006","journal-title":"Drugs"},{"issue":"Suppl 17","key":"10.1016\/j.mehy.2011.11.008_b0220","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1399-0012.2006.00597.x","article-title":"Antifibrotic actions of mycophenolic acid","volume":"20","author":"Morath","year":"2006","journal-title":"Clin Transplant"},{"key":"10.1016\/j.mehy.2011.11.008_b0225","doi-asserted-by":"crossref","first-page":"L212","DOI":"10.1152\/ajplung.00475.2006","article-title":"Nitric oxide attenuates epithelial-mesenchymal transition in alveolar epithelial cells","volume":"293","author":"Vyas-Read","year":"2007","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.mehy.2011.11.008_b0230","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1139\/Y08-047","article-title":"Pulmonary fibrosis in L-NAME-treated mice is dependent on an activated endothelin system","volume":"86","author":"Kalk","year":"2008","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.mehy.2011.11.008_b0235","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1046\/j.1523-1755.2003.00112.x","article-title":"NO mediates antifibrotic actions of L-arginine supplementation following induction of anti-thy1 glomerulonephritis","volume":"64","author":"Peters","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.mehy.2011.11.008_b0240","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.2174\/138161205774913372","article-title":"The pleiotropic effects of inducible nitric oxide synthase (iNOS) on the physiology and pathology of penile erection","volume":"11","author":"Gonzalez-Cadavid","year":"2005","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.mehy.2011.11.008_b0245","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1095\/biolreprod.104.030833","article-title":"Gene transfer of inducible nitric oxide synthase complementary DNA regresses the fibrotic plaque in an animal model of Peyronie\u2019s disease","volume":"71","author":"Davila","year":"2004","journal-title":"Biol Reprod"},{"key":"10.1016\/j.mehy.2011.11.008_b0250","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1006\/niox.2001.0421","article-title":"Antifibrotic role of inducible nitric oxide synthase","volume":"6","author":"Ferrini","year":"2002","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.mehy.2011.11.008_b0255","doi-asserted-by":"crossref","DOI":"10.1111\/j.1743-6109.2010.01884.x","article-title":"The genetic inactivation of inducible nitric oxide synthase (iNOS) intensifies fibrosis and oxidative stress in the penile corpora cavernosa in type 1 diabetes","author":"Ferrini","year":"2010","journal-title":"J Sex Med"},{"key":"10.1016\/j.mehy.2011.11.008_b0260","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0002-9440(10)65700-8","article-title":"Collagen deposition in a non-fibrotic lung granuloma model after nitric oxide inhibition","volume":"153","author":"Hogaboam","year":"1998","journal-title":"Am J Pathol"},{"key":"10.1016\/j.mehy.2011.11.008_b0265","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1161\/01.HYP.30.5.1035","article-title":"Effect of nitric oxide on DNA replication induced by angiotensin II in rat cardiac fibroblasts","volume":"30","author":"Takizawa","year":"1997","journal-title":"Hypertension"},{"key":"10.1016\/j.mehy.2011.11.008_b0270","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1464-410X.2006.05955.x","article-title":"Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie\u2019s disease","volume":"97","author":"Ferrini","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.mehy.2011.11.008_b0275","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.2174\/138161210791164162","article-title":"Exploring the potential of NO-independent stimulators and activators of soluble guanylate cyclase for the medical treatment of erectile dysfunction","volume":"16","author":"Gur","year":"2010","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.mehy.2011.11.008_b0280","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1164\/rccm.200707-1121OC","article-title":"Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation","volume":"176","author":"Evgenov","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.mehy.2011.11.008_b0285","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejphar.2007.06.036","article-title":"Inhibition of TGF-beta induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase","volume":"572","author":"Dunkern","year":"2007","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.mehy.2011.11.008_b0290","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1161\/01.HYP.0000241087.12492.47","article-title":"Soluble guanylate cyclase stimulation on cardiovascular remodeling in angiotensin II-induced hypertensive rats","volume":"48","author":"Masuyama","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.mehy.2011.11.008_b0295","doi-asserted-by":"crossref","first-page":"F167","DOI":"10.1152\/ajprenal.00197.2005","article-title":"Enhancing cGMP in experimental progressive renal fibrosis: soluble guanylate cyclase stimulation vs. phosphodiesterase inhibition","volume":"290","author":"Wang","year":"2006","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.mehy.2011.11.008_b0300","first-page":"71","article-title":"Nitric oxide-independent activation of soluble guanylate cyclase by BAY 60-2770 in experimental liver fibrosis","volume":"58","author":"Knorr","year":"2008","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.mehy.2011.11.008_b0305","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0021-9150(99)00030-1","article-title":"Overexpression of tissue-type plasminogen activator in atherosclerotic human coronary arteries","volume":"145","author":"Steins","year":"1999","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.mehy.2011.11.008_b0310","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1038\/sj.mt.6300250","article-title":"Decorin gene transfer promotes muscle cell differentiation and muscle regeneration","volume":"15","author":"Li","year":"2007","journal-title":"Mol Ther"},{"key":"10.1016\/j.mehy.2011.11.008_b0315","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/ncpuro0201","article-title":"Mechanisms of disease: new insights into the cellular and molecular pathology of Peyronie\u2019s disease","volume":"2","author":"Gonzalez-Cadavid","year":"2005","journal-title":"Nat Clin Pract Urol"},{"key":"10.1016\/j.mehy.2011.11.008_b0320","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1517\/14712598.6.2.147","article-title":"The role of myostatin and bone morphogenetic proteins in muscular disorders","volume":"6","author":"Tsuchida","year":"2006","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.mehy.2011.11.008_b0325","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0065-2423(06)43004-3","article-title":"Activin A in brain injury","volume":"43","author":"Florio","year":"2007","journal-title":"Adv Clin Chem"},{"key":"10.1016\/j.mehy.2011.11.008_b0330","doi-asserted-by":"crossref","DOI":"10.1111\/j.1743-6109.2010.01753.x","article-title":"Transforming growth factor (TGF)-beta type I receptor kinase (ALK5) inhibitor alleviates profibrotic TGF-beta1 responses in fibroblasts derived from Peyronie\u2019s plaque","author":"Piao","year":"2010","journal-title":"J Sex Med"},{"key":"10.1016\/j.mehy.2011.11.008_b0335","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/abbs\/gmp018","article-title":"Regulation of TGF-beta signaling by Smad7","volume":"41","author":"Yan","year":"2009","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"10.1016\/j.mehy.2011.11.008_b0340","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/0014-5793(90)81322-F","article-title":"Involvement of thymosin beta 4 and endoproteinase Asp-N in the biosynthesis of the tetrapeptide AcSerAspLysPro a regulator of the hematopoietic system","volume":"274","author":"Grillon","year":"1990","journal-title":"FEBS Lett"},{"issue":"Pt 12","key":"10.1016\/j.mehy.2011.11.008_b0345","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1242\/jcs.108.12.3685","article-title":"Matrigel induces thymosin beta 4 gene in differentiating endothelial cells","volume":"108","author":"Grant","year":"1995","journal-title":"J Cell Sci"},{"key":"10.1016\/j.mehy.2011.11.008_b0350","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1096\/fasebj.11.6.9194528","article-title":"Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells","volume":"11","author":"Malinda","year":"1997","journal-title":"FASEB J"},{"key":"10.1016\/j.mehy.2011.11.008_b0355","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1006\/exer.2000.0985","article-title":"Thymosin beta 4 promotes corneal wound healing and modulates inflammatory mediators in vivo","volume":"72","author":"Sosne","year":"2001","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.mehy.2011.11.008_b0360","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1096\/fj.03-0244fje","article-title":"Thymosin beta4 increases hair growth by activation of hair follicle stem cells","volume":"18","author":"Philp","year":"2004","journal-title":"FASEB J"},{"key":"10.1016\/j.mehy.2011.11.008_b0365","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.urology.2004.04.006","article-title":"Comparison of gene expression profiles between Peyronie\u2019s disease and Dupuytren\u2019s contracture","volume":"64","author":"Qian","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.mehy.2011.11.008_b0370","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejphar.2008.06.110","article-title":"Potent antioxidant role of pirfenidone in experimental cirrhosis","volume":"595","author":"Salazar-Montes","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.mehy.2011.11.008_b0375","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1586\/ers.10.32","article-title":"Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis","volume":"4","author":"Azuma","year":"2010","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.mehy.2011.11.008_b0380","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.cardiores.2005.12.002","article-title":"Structure and function of matrix metalloproteinases and TIMPs","volume":"69","author":"Nagase","year":"2006","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.mehy.2011.11.008_b0385","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1111\/j.1743-6109.2010.01915.x","article-title":"The relationship between androgens, regulators of collagen metabolism, and Peyronie\u2019s disease: a case control study","volume":"7","author":"Karavitakis","year":"2010","journal-title":"J Sex Med"},{"key":"10.1016\/j.mehy.2011.11.008_b0390","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-540-89615-9_1","article-title":"Introduction to adenosine receptors as therapeutic targets","author":"Jacobson","year":"2009","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.mehy.2011.11.008_b0395","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1096\/fj.09-144147","article-title":"Increased adenosine contributes to penile fibrosis, a dangerous feature of priapism, via A2B adenosine receptor signaling","volume":"24","author":"Wen","year":"2010","journal-title":"FASEB J"},{"key":"10.1016\/j.mehy.2011.11.008_b0400","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/sj.gt.3301545","article-title":"Systemic administration of naked plasmid encoding hepatocyte growth factor ameliorates chronic renal fibrosis in mice","volume":"8","author":"Yang","year":"2001","journal-title":"Gene Ther"},{"key":"10.1016\/j.mehy.2011.11.008_b0405","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1046\/j.1523-1755.2001.0590041304.x","article-title":"Hepatocyte growth factor suppresses interstitial fibrosis in a mouse model of obstructive nephropathy","volume":"59","author":"Mizuno","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.mehy.2011.11.008_b0410","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.2337\/diabetes.53.4.1119","article-title":"Regression of advanced diabetic nephropathy by hepatocyte growth factor gene therapy in rats","volume":"53","author":"Cruzado","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.mehy.2011.11.008_b0415","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1517\/13543780903501539","article-title":"Pirfenidone: an anti-fibrotic therapy for progressive kidney disease","volume":"19","author":"Cho","year":"2010","journal-title":"Expert Opin Invest Drugs"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987711005809?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987711005809?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,12,19]],"date-time":"2021-12-19T17:35:55Z","timestamp":1639935355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987711005809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":83,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S0306987711005809"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2011.11.008","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}